TTrialPathMatch Me to Trials
← Back to trials
RecruitingOsteoarthritis

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip

Eligible age

18–90 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.

Sponsor: VivaTech International, Inc.

You may qualify if…

  • ✓ 1. Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
  • ✓ 2. Patients range from 18-90 years of age.
  • ✓ 3. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
  • ✓ 4. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
  • ✓ 5. Patients with adequate cardiac and respiratory function.
  • ✓ 6. Patients with adequate blood coagulation activity, PT(INR) \< 1.5, APTT
  • ✓ 7. Patients must have adequate immune system function, with no known immunodeficiency disease.
  • ✓ 8. Greater than 6 months hip pain with the index side (left or right).

You may not qualify if…

  • ✕ 1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
  • ✕ 2. Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke).
  • ✕ 3. Diagnosis of a transient ischemic attack in the 6 months prior to screening.
  • ✕ 4. Patients infected with hepatitis B, C or HIV.
  • ✕ 5. Patients with Body Mass Index (BMI) \> 40kg/m2
  • ✕ 6. Presence of active infection.
  • ✕ 7. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
  • ✕ 8. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:

Where it's recruiting

Pennsylvania

Grove City

Source: ClinicalTrials.gov · NCT02844764 · last updated 2025-10-14

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain · TrialPath